top
Please input keywords
OK
Database
홍보센터
Contact us
KR
CN
EN
JP
회사소개
회사소개
회사 연혁
핵심인력
기업문화
사회적 책임
인재모집
합작연구개발
Antibody Assets
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
동물/세포 모델
Pharmacology service
유전자 편집
Collaborations
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
합작연구개발
파트너쉽
신약의 조기 출시를 위한 오픈 이노베이션
Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.
Collaboration Models
Antibody Out-licensing
Antibody Co-Development
Antibody Transfer
Technology Platform Out-licensing
Various drug modalities
Monoclonal Antibody
Bispecific Antibody
Bispecific ADC
Nanobodie
TCRm Antibody
Cell Therapy
Established partnerships
103
103 therapeutic antibody co-development/out-licensing/transfer agreements
47
47 target-nominated RenMice licensing projects
5
5 pipeline-based co-development
Disclosed Partners
Worldwide antibody assets or platform partners include Gilead, Merck KGaA, Janssen, Xencor, ADC Therapeutics, Neurocrine Biosciences, Radiance Biopharma, RemeGen and BeiGene.
Contact us for antibody assets and platforms partnership opportunities at BD-Licensing@biocytogen.com.
Antibody discovery platforms